Suggested remit: To appraise the clinical and cost effectiveness of trifluridine–tipiracil with bevacizumab within its marketing authorisation for treating metastatic colorectal cancer after 2 systemic treatments.
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6298

Provisional Schedule

Expected publication 25 September 2024

Project Team

Project lead Jeremy Powell

Email enquiries

External Assessment Group Health Economics Research Unit and Health Services Research Unit, University of Aberdeen


Companies sponsors Servier
Others Department of Health and Social Care
  NHS England
Patient carer groups Bowel Cancer UK
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
Comparator companies Bayer (regorafenib) CAU signed -participating
  Bristol Myers Squibb (ipilimumab, nivolumab) CAU not signed (not participating)
  Hospira UK (irinotecan, fluorouracil, oxaliplatin, raltitrexed) CAU not signed (not participating)
  Medac GmbH (fluorouracil, folinic acid, irinotecan, oxaliplatin) CAU not signed (not participating)
  Merck Serono (cetuximab) CAU signed- participating
  Pierre Fabre (encorafenib) CAU not signed (not participating)
  Pfizer (bevacizumab, irinotecan) CAU signed- participating
  Ranbaxy (irinotecan, oxaliplatin) CAU not signed (not participating)
  Seacross Pharmaceuticals (irinotecan, oxaliplatin) CAU not signed (not participating)
  Celltrion Healthcare (bevacizumab) CAU not signed (not participating)
  Organon Pharma (bevacizumab) CAU not signed (not participating)
  Roche (bevacizumab) CAU signed- participating
  Thornton & Ross (bevacizumab) CAU not signed (not participating)
  Zentiva (bevacizumab) CAU signed- Participating
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research
  National Institute for Health Research


Key events during the development of the guidance:

Date Update
11 July 2024 Committee meeting: 2
06 June 2024 - 27 June 2024 Draft guidance
15 May 2024 Committee meeting: 1
15 May 2024 Declaration of interests
11 October 2023 Invitation to participate
07 August 2023 - 05 September 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
07 August 2023 In progress. Scoping Commenced

For further information on our processes and methods, please see our CHTE processes and methods manual